TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02016807

Intervention type: DEVICE
Intervention: ProThelial
Description: August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.

Intervention type: DEVICE
Intervention: ProThelial
Description: August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.

Intervention type: DEVICE
Intervention: ProThelial
Description: August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
Study: NCT02849496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT00675142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: Changing the time span between ovulation induction and IUI during fertility treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: Changing the time span between ovulation induction and IUI during fertility treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: Changing the time span between ovulation induction and IUI during fertility treatment.
Study: NCT04715295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Tablets
Description: Doxycycline 200 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15Mg Tab
Description: Rivaroxaban 15 mg tablets daily from day 1 to day 10

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
Study: NCT02702245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Thylakoids 5 g
Description: 75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Thylakoids 10 g
Description: 75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: 75 g pure glucose.
Study: NCT04449029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Study: NCT02285244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin acetate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00180453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery drug eluting stent placement
Description: Coronary artery drug eluting stent placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery stent placement
Description: Coronary artery stent placement
Study: NCT04251936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation group program
Description: Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation group program
Description: Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
Study: NCT02171208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Reference form
Description: single dose 240 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Reference form
Description: single dose 240 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Test form
Description: single dose 240 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Test form
Description: single dose 240 mg
Study: NCT05192785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry Group
Description: The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it.
Study: NCT02046187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients receive standard dose (60Gy/30 fractions) external beam radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
Study: NCT02825537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification

Intervention type: OTHER
Group type: OTHER
Intervention: No use of compression stocking
Description: No use of compression stocking
Study: NCT00202995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: 20 mg s.c. daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron
Description: 250 mg every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Description: 44 ug 3 times a week
Study: NCT00565760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT01272856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 125 mg pre-filled syringe for sub-q injection weekly.
Study: NCT01049672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Titrated to a maximum dose of 50mg in 24 hours subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamorphine
Description: Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
Study: NCT02818062

Intervention type: BIOLOGICAL
Intervention: Cytokines dosage in Aqueous humor
Description: Specify details not covered in associated Arm Description.

Intervention type: BIOLOGICAL
Intervention: Cytokines dosage in Aqueous humor
Description: Specify details not covered in associated Arm Description.
Study: NCT02369250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, is a statin group of drug.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin
Description: AUTOLOGUS PLATELET GROWTH FACTOR
Study: NCT03786055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Yoga and Meditation (SYM)
Description: A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
Study: NCT00729807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentamidine
Study: NCT00581997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04781985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: extraction of the bladder stone via suprapubic incision
Study: NCT01524185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyLive
Description: Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mental Health Treatment
Description: Standard trauma-informed mental health treatment
Study: NCT01887522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine + Nilotinib
Description: * Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: · Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
Study: NCT01881165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01471353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Plus Capecitabine (SorCape)
Description: Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Study: NCT02115165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
Study: NCT02818530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOP by tonometer
Description: Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior chamber depth measurement by ultrasound
Description: Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
Study: NCT00932841

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One packet PO daily x 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 900 billion bacteria
Description: One packet PO daily, x 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 90 billion bacteria
Description: One packet PO daily, x 8 weeks.
Study: NCT02760927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube Fastener
Description: The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
Study: NCT00012974

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Provider education, computer reminders, nurse case management
Study: NCT03606174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Study: NCT01547286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standardized Cat Allergen Extract and Standardized Dust Mite Allergen
Description: The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography imaging, functional Positron Emission Tomography imaging
Description: Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized methacholine inhalation
Description: Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.